Pancreatic DiseasesNCT07022639
Influence of Hospital Volume on Mortality and Length of Hospital Stay After Pancreatic Resection in Switzerland
An observational study of Pancreatic Diseases, run by Cantonal Hospital of St. Gallen at 1 site in Switzerland.
Trial summary
The effect of centralisation measures on the operative outcomes after pancreatic resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of pancreatic resection on short-term postoperative outcomes. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Pancreatic Diseases
- What is being tested?
- Total pancreatectomy, Proximal pancreatectomy and Distal pancreatectomy
- Type of treatment
- Surgery or procedure
- How many people
- 6,785 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2013to 1 Mar 2023
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Adult, Older adult
Study population: All patients with pancreatic resection in Switzerland between 2013 and 2022.
Who may be able to join
- All patients with pancreatic resection in Switzerland between 2013 and 2022
Who cannot join
- incomplete case documentation
- age under 20 years
- other hospitals than general or surgical hospitals
- no index operation
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
HOCH Health Ostschweiz, Kantonsspital St.Gallen
Sankt Gallen, St.Gallen, 9000
About this study
Official title: Influence of Hospital Volume on Mortality and Length of Hospital Stay After Pancreatic Resection in Switzerland: A Retrospective National Registry Study
The effect of centralisation measures on the operative outcomes after pancreatic resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of pancreatic resection on short-term postoperative outcomes.
- Conditions
- Pancreatic Diseases
- Being tested
- Total pancreatectomy, Proximal pancreatectomy, Distal pancreatectomy
- Medical subject headings
- Pancreatic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total pancreatectomyProcedure or surgery
Total pancreatectomy for any kind of disease
Proximal pancreatectomyProcedure or surgery
Proximal pancreatectomy for any kind of disease
Distal pancreatectomyProcedure or surgery
Distal pancreatectomy for any kind of disease
| Study group | Role | What they receive |
|---|---|---|
| Total pancreatectomy | Not described Receives: Procedure: Total pancreatectomy | |
| Proximal pancreatectomy | Not described Receives: Procedure: Proximal pancreatectomy | |
| Distal pancreatectomy | Not described Receives: Procedure: Distal pancreatectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
The association between the hospital volume and the postoperative mortality Mortality Yes or No Hospital volume of pancreatic resection as marginal effect Association with GAM logistic regression
Measured: Periprocedural
Secondary outcomes (3)
Reoperation
The association between the hospital volume and the reoperation rate Reoperation Yes or No Hospital volume of pancreatic resection as marginal effect Association with GAM logistic regression
Measured: Periprocedural
Length of hospital stay
The association between the hospital volume and the length of hospital stay Length of hospital stay in days Hospital volume of pancreatic resection as marginal effect Association with quantile regression
Measured: Periprocedural
Sociodemographic trends
Measured: 2013 - 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2025
- Study start1 Jan 2013
- Primary completion31 Dec 2022
- Study completion1 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6,785 participants (actual)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- Cantonal Hospital of St. Gallen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yanic Ammann, Cantonal Hospital of St. Gallen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07022639
- Sponsor's protocol ID
- Hospital volume PR
- Status last verified
- Jul 2025
- First submitted
- 26 May 2025
- Last updated
- 10 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Hospital Volume on Mortality and Length of Hospital Stay After Pancreatic Resection in Switzerland: A Retrospective National Registry Study
- ClinicalTrials.gov ID
- NCT07022639
- Acronym / sponsor ID
- Hospital volume PR
- Conditions
- Pancreatic Diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 6,785 participants (actual)
- Lead sponsor
- Cantonal Hospital of St. GallenUniversity, hospital or other
- Study start
- 1 Jan 2013 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 1 Mar 2023 (actual)
- First posted
- 15 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The effect of centralisation measures on the operative outcomes after pancreatic resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of pancreatic resection on short-term postoperative outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Total pancreatectomy | – | Procedure: Total pancreatectomy |
| Proximal pancreatectomy | – | Procedure: Proximal pancreatectomy |
| Distal pancreatectomy | – | Procedure: Distal pancreatectomy |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients with pancreatic resection in Switzerland between 2013 and 2022.
Key inclusion criteria (1 listed)
- All patients with pancreatic resection in Switzerland between 2013 and 2022
Key exclusion criteria (4 listed)
- incomplete case documentation
- age under 20 years
- other hospitals than general or surgical hospitals
- no index operation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total pancreatectomyTotal pancreatectomy for any kind of disease | Procedure or surgery | Total pancreatectomy |
| Proximal pancreatectomyProximal pancreatectomy for any kind of disease | Procedure or surgery | Proximal pancreatectomy |
| Distal pancreatectomyDistal pancreatectomy for any kind of disease | Procedure or surgery | Distal pancreatectomy |
Primary outcome
Mortality
Time frame: Periprocedural
The association between the hospital volume and the postoperative mortality Mortality Yes or No Hospital volume of pancreatic resection as marginal effect Association with GAM logistic regression
3 secondary outcomes
Reoperation
Time frame: Periprocedural
Length of hospital stay
Time frame: Periprocedural
Sociodemographic trends
Time frame: 2013 - 2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Pancreatic Diseases
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Diseases, run by Cantonal Hospital of St. Gallen at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: Periprocedural). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2025.